Dr Palace is Consultant Neurologist in Oxford and runs the regional MS service and General neurology for the Banbury area.
She is Lead for the national Congenital Myasthenia service and also runs a joint National Neuromyelitis Service with the Walton Centre Liverpool.
She is a clinical lead for the UK MS risk sharing scheme study assessing the long term effects of beta-interferon and Copaxone.
On Oct 2011 she has published over 80 papers and reviews.
Awards Training and Qualifications
- 1983 BM Honours and Clinical Distinction, SOTON
- 1986 MRCP, SOTON
- 1992 DM, SOTON
- 1995 Accredited Neurology
- 2000 FRCP
BM (Hons) FRCP DM
- Oxford Multiple Sclerosis and Neuromyelitis Group
Neuromyelitus optica, multiple sclerosis and myasthenia
Dr. Palace leads the Oxford Multiple Sclerosis and Neuromyelitis Group. This comprises a regional clinical service and a clinical research group. Research topics include clinical treatment trials, immunological studies, biomarkers and imaging studies on neurodegeneration and its detection and association with inflammation. The group welcomes referrals of patients.
Sources of Funding
A novel phenotype of AChR-deficiency syndrome with predominant facial and distal weakness resulting from the inclusion of an evolutionary alternatively-spliced exon in CHRNA1
Rodríguez Cruz PM. et al, (2023), Neuromuscular Disorders, 33, 161 - 168
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination.
Francis AG. et al, (2023), Neurol Neuroimmunol Neuroinflamm, 10
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T. et al, (2023), Neurol Neuroimmunol Neuroinflamm, 10
Anterior optic pathway pathology in CNS demyelinating diseases
Pisa M. et al, (2022), Brain, 145, 4308 - 4319
Should We Test for IgG Antibodies Against MOG in Both Serum and CSF in Patients With Suspected MOGAD?
Kim HJ. and Palace J., (2022), Neurology